IL-25 blockade inhibits metastasis in breast cancer

Abstract Metastasis is the leading cause of death in breast cancer patients. However, the mechanisms underlying metastasis are not well understood and there is no effective treatment in the clinic. Here, we demonstrate that in MMTV-PyMT, a highly malignant spontaneous breast tumor model, IL-25 (also...

Full description

Bibliographic Details
Main Authors: Zhujun Jiang, Jingtao Chen, Xuemei Du, Hang Cheng, Xiaohu Wang, Chen Dong
Format: Article
Language:English
Published: Oxford University Press 2016-12-01
Series:Protein & Cell
Subjects:
Online Access:http://link.springer.com/article/10.1007/s13238-016-0345-7
Description
Summary:Abstract Metastasis is the leading cause of death in breast cancer patients. However, the mechanisms underlying metastasis are not well understood and there is no effective treatment in the clinic. Here, we demonstrate that in MMTV-PyMT, a highly malignant spontaneous breast tumor model, IL-25 (also called IL-17E) was expressed by tumor-infiltrating CD4+ T cells and macrophages. An IL-25 neutralization antibody, while not affecting primary tumor growth, substantially reduced lung metastasis. Inhibition of IL-25 resulted in decreased type 2 T cells and macrophages in the primary tumor microenvironments, both reported to enhance breast tumor invasion and subsequent metastasis to the lung. Taken together, our data suggest IL-25 blockade as a novel treatment for metastatic breast tumor.
ISSN:1674-800X
1674-8018